#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Internal Medicine / 2018 - 7-8

Controversies in the treatment of gout

Česká verzia

Authors: Štefan Alušík 1;  Zoltán Paluch 2
Authors place of work: Katedra vnitřního lékařství IPVZ, Praha 1;  Ústav farmakologie 2. LF UK, Praha 2
Published in the journal: Vnitř Lék 2018; 64(7-8): 753-761
Category: Reviews

Summary

The authors discuss current options on the treatment of gout (acute gout attack, prophylaxis, management of hypouricemia) and asymptomatic hyperuricemia. They highlight the differences in individual guidelines in terms of the spectrum of drugs used, their preferences, dosing, dose titration, and goals of treatment as well as different positions over asymptomatic hyperuricemia. Further, the authors provide an overview of latest concepts related to uric acid and its association with some neurologic and cardiovascular diseases. Another issues discussed in the article are the completely different guidelines for general practitioners and their principles. In conclusion, the authors note that answers to some controversies in the treatment of gout can only be provided by data obtained from properly designed and conducted clinical trials.

Key words:

allopurinol – colchicine – glucocorticoids – gout – non-steroidal anti-inflammatory drugs – uric acid

Zdroje
  1. Graf SW, Whittle SL, Wechalekar MD et al. Australian and New Zealand recommendations for the diagnosis and management of gout:integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis 2015; 18(3): 341–351. Dostupné z DOI: <http://dx.doi.org/10.1111/1756–185X.12557>.
  2. Manara M, Bortoluzzi A, Favero M et al. Italian Society of Rheumatology recommendation for the management of gout. Rheumatismo 2013; 65(1): 4–21. Dostupné z DOI: <http://dx.doi.org/10.4081/reumatismo.2013.4>.
  3. [Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases]. Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases. Chin Med J 2017; 130(20): 24732488. Dostupné z DOI: <http://dx.doi.org/10.4103/0366–6999.216416>.
  4. Yamanaka H. Japanese Society of Gout and Nucleic Acid Metabolism.Japanese guideline for the management of hyperuricemia and gout:second edition. Nucleosides Nucleotides Nucleic Acids 2011; 30(12): 1018–1029. Dostupné z DOI: <http://dx.doi.org/10.1080/15257770.2011.596496>.
  5. Qaseem A, Harris RP, Forciea AF et al. Management of acute and recurrent gout:A clinical practice guidelines from the American College of Physicians. Ann Intern Med 2017; 166(1): 58–68. Dostupné z DOI: <http://dx.doi.org/10.7326/M16–0570>.
  6. Khanna D, FitzGerald JD, Khanna PP et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64(10): 1431–1446. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21772>.
  7. Khanna D, Khanna PP, FitzGerald JD et al. 2012 American College of Rheumatology Guidelines for Management of Gout Part II.Therapy and Anti-inflammatory Prophylaxis of acute Gouty Arthritis. Arthritis Care Res (Hoboken) 2012; 64(10): 1447–1461. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21773>.
  8. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendation for the management of gout. Ann Rheum Dis 2017; 76(1): 29–42. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2016–209707>.
  9. Sivera F, Andrés M, Carmona L et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014; 73(2): 328–335. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013–203325>.
  10. Hui M, Carr A, Cameron S et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology 2017; 56(7): e1-e20. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kex156>.
  11. Keenan RT, O´Brien WR, Lee KH et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011; 124(2): 155–163. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2010.09.012>.
  12. Puschmann T. Alexander von Tralles: Original-Text und Übersetzung nebst einer einleitenden Abhandlung: ein Beitrag zur Geschichte der Medicin. 2voll. Wilhelm Braumüller: Wien 1878–1879: vol. I: 75–87.
  13. Terkeltaub RA, Furst DE, Bennett K et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four- hour outcome of the first multicenter,randomized, double-blind,placebo-controlled,parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62(4): 1060–1068. Dostupné z DOI: <http://dx.doi.org/10.1002/art.27327>.
  14. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65(10): 1312–1324. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2006.055269>.
  15. Frydrychowicz C, Pasieka B, Pierer M et al. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report. J Med Case Rep 2017; 11(1): 8. Dostupné z DOI: <http://dx.doi.org/10.1186/s13256–016–1169-z>.
  16. Kwon OC, Chang B, Kim YG et al. Risk of colchicine in gout:Influence of concomitant use of statin. Am J Med 2017; 130(5): 583–587. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2016.12.006>.
  17. Ayubi E, Safiri S. Risk of colchicine-associated myopathy in gout: Influence of concomitant use of statin; Methodologic issues. (Lett). Am J Med 2017; 130(10): e467. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2017.04.032>.
  18. van Durme CM, Wechalekar MD, Buchbinder R et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; (9): CD010120. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD010120.pub2>.
  19. [No authors listed]. NSAIDs and serious cardiovascular disorders:especially cox-2 inhibitors and diclofenac. Prescrire Int 2016; 25(167): 14–16.
  20. Janssens HJ, Janssen M, van de Lisdonk EH et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371(9627): 1854–1860. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60799–0>.
  21. Becker MA. Treatment of acute gout.UptoDate. 2018. Dostupné z WWW: <https://www.uptodate.com/contents/treatment-of-acute-gout>.
  22. Gutman AB, Yü TF. Effects of adrenocorticotropic hormone (ACTH) in gout. Am J Med 1950; 9(1): 24–30.
  23. Daoussis D, Antonopoulos I, Yiannopoulos G et al. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine 2013; 80(3): 291–294. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2012.09.009>.
  24. Martinon F, Pétrilli V, Mavor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440(7081): 237–241. Dostupné z DOI: <http://dx.doi.org/10.1038/nature04516>.
  25. Schlesinger N, Alten RE, Bardin T et al. Canacinumab for acute gouty arthritis in patients with limited treatment options:result from two randomised,multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71(11): 1839–1848. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2011–200908>.
  26. Ottaviani S, Molto A, Ea HK et al. Efficacy of anakinra in gouty arthritis:a retrospective study of 40 cases. Arth Res Ther 2013; 15(5): R123.
  27. Terkeltaub RA, Schumacher HR, Carter JD et al. Rilonacept in the treatment of acute gouty arthritis:a randomized,controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013; 15(1): R25. Dostupné z DOI: <http://dx.doi.org/10.1186/ar4159>.
  28. Mitha E, Schumacher R, Fouche L et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy:result from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013; 52(7): 1285–1292. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket114>.
  29. Bernal JA, Quilis N, Andrés M et al. Gout: optimizing treatment to achieve a disease cure. Ther Adv Chronic Dis 2016; 7(2): 135–144. Dostupné z DOI: <http://dx.doi.org/10.1177/2040622315618393>.
  30. Karimzadeh H, Nazari J, Mottaghi P et al. Different duration of colchicine for prevention recurrence of gouty arthritis. J Res Med Sci 2006; 11(2): 104–107.
  31. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther 2015; 32(1): 31–41. Dostupné z DOI: <http://dx.doi.org/10.1007/s12325–014–0175-z>.
  32. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford) 2007; 46(8): 1372–1374. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kem056a>.
  33. Hill EM, Sky K, Sit M et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015; 21(3): 120–125. Dostupné z DOI: <http://dx.doi.org/10.1097/RHU.0000000000000235>.
  34. Taylor T, Mecchella J, Larson R et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012; 125(11): 1126–1134.e7. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2012.05.025>.
  35. De Vera MA, Marcotte G, Rai S et al. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken) 2014; 66(10): 1551–1559. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.22336>.
  36. Mantarro S, Capogrosso-Sansone A, Tuccori M et al. Allopurinol adherence among patients with gout:an Italian general practice database study. Int J Clin Pract 2015; 69(7): 757–765. Dostupné z DOI: <http://dx.doi.org/10.1111/ijcp.12604>.
  37. Jansen TL, Jansen M. The American College of Physicians and the 2017 guideline for the management of acute and recurrent gout:treat to avoiding symptoms versus treat to target. Clin Rheumatol 2017; 36(11): 2399–2402. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–017–3840–1>.
  38. Dalbeth N, Bardin T, Doherty M et al. Discordant American College of Physicians and international rheumatology guidelines for gout management:consensus statement of the Gout,Hyperuricemia a Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol 2017; 13(9): 561–568. Dostupné z DOI: <http://dx.doi.org/10.1038/nrrheum.2017.126>.
  39. Newberry SJ, Fitz Gerald JD, Motala A et al. Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2017; 166(1): 27–36. Dostupné z DOI: <http://dx.doi.org/10.7326/M16–0462>.
  40. Shekelle PG, Newberry SJ, FitzGerald JD et al. Management of gout:A systematic review in support of an American College of Physicians Clinical Practice Guidelines. Ann Intern Med 2017; 166(1): 37–51. Dostupné z DOI: <http://dx.doi.org/10.7326/M16–0461>.
  41. Reinders MK, Haagsma C, Jansen TL et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 2009; 68(6): 892–897. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2008.091462>.
  42. Stamp LK, Chapman PT, Barclay ML et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 2017; 76(9): 1522–1528. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2016–210872>.
  43. Dalbeth N, Nicolaou S, Baumgartner S et al. Presence of monosodium of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. Ann Rheum Dis 2018; 77(3): 364–370. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2017–212046>.
  44. Stamp LK, Taylor WJ, Jones PB et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome. A proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64(8): 2529–2536. Dostupné z DOI: <http://dx.doi.org/10.1002/art.34488>.
  45. Uloric (febuxostat): Drug Safety Communication – FDA to Evaluate Increased Risk of Heart-related Death. Dostupné z WWW: <https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm585281.html>.
  46. Miner JT, Tan PK, Hyndman D et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther 2016; 18(1): 214. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075–016–1107-x>.
  47. Bardin T, Keenan RT, Khanna PP et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017; 76(5): 811–820. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2016–209213>.
  48. Yu X, Liu L, Nie X et al. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis. J Clin Pharm Ther 2017; 42(1): 18–26. Dostupné z DOI: <http://dx.doi.org/10.1111/jcpt.12479>.
  49. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Cur Opin Rheumatol 2014; 26(2): 186–191. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0000000000000028>.
  50. Ma L, Li X, Zhou Z et al. New insight into hypouricemia. Gout and Hyperuricemia 2016; 3(3): 71–77. Dostupné z DOI: <http://dx.doi.org/10.3966/GH1609030302>.
  51. Andres M, Quintanilla MA, Sivera P et al. Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. Arthritis Rheumatol 2016; 68(6): 1531–1539. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39581>.
  52. Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia:is it time to intervene? Clin Rheumatol 2017; 36(12): 2637–2644. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–017–3851-y>.
  53. Levy G, Cheetham TC. Is it time to start treating asymptomatic hyperuricemia? Am J Kidney Dis 2015; 66(6): 933–935. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2015.09.002>.
  54. Guo L. Interpretation of the Chinese expert consensus: Recomendations for diagnosis of treatment of asymptomatic hyperuricemia complicated with cardiovascular diseases. J Transl Intern Med 2014; 2(3): 93–96. Dostupné z DOI: <http://dx.doi.org/10.4103/2224–4018.135617>.
  55. Cantor JR, Abu-Remaileh M, Kanarek N et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase. Cell 2017; 169(2): 258–272. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2017.03.023>.
  56. Kang DH, Ha SK. Uric acid puzzle: dual role as anti-oxidant and pro-oxidant. Electrolyte Blood Press 2014; 12(1): 1–6. Dostupné z DOI: <http://dx.doi.org/10.5049/EBP.2014.12.1.1>
  57. Kanbay M, Jensen T, Solak Y et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med 2016; 29: 3–8. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2015.11.026>.
  58. Fang P, Li X, Luo JJ et al. A double-edged sword:uric acid and neurological disorders. Brain Disord Ther 2013; 2(2): 109. Dostupné z DOI: <http://dx.doi.org/10.4172/2168–975X.1000109>.
  59. Lu N, Dubreuil M, Zhang Y et al. Gout and the risk of Alzheimer´s disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 2016; 75(3): 547–551. <http://dx.doi.org/10.1136/annrheumdis-2014–206917>.
  60. Li M, Hu X, Li K et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose – response meta-analysis. Sci Rep 2016; 6: 19520. Dostupné z DOI: <http://dx.doi.org/10.1038/srep19520>.
  61. Liu P, Wang H, Zhang F et al. The effect of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: A three-year randomized parallel-controlled study. Intern Med 2015; 54(17): 2129–2137. Dostupné z DOI: <http://dx.doi.org/10.2169/internalmedicine.54.4310>.
  62. Sircar D, Chatterjee S, Wikhom R et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2015; 66(6): 945–950. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2015.05.017>.
  63. Johnson RJ, Nakagawa T, Jalal D et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013; 28(9): 2221–2228. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gft029>.
  64. Capuano V, Marchese F, Capuano R et al. Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med (Hagerstown) 2017; 18(3): 159–164. Dostupné z DOI: <http://dx.doi.org/10.2459/JCM.0000000000000347>.
  65. Pavelka K. Diagnostika a terapie dny. Vnitř Lék 2015; 61(6): 517–526.
  66. Alušík T, Alušík Š. Tradiční medicína a současnost: terapie dny. Čas Lék Čes 2017; 156(8): 454–457.
  67. McLean RM. The long and winding road to clinical guidelines on the diagnosis and management of gout. Ann Intern Med 2017; 166(1): 73–74. Dostupné z DOI: <http://dx.doi.org/10.7326
Štítky
Diabetology Endocrinology Internal medicine
Článek The Scottish model of vancomycin dosing and therapeutic drug monitoring improves both efficacy and safety of vancomycin therapy
Článek Mesenchymal stem cells and type 1 diabetes treatment
Článek How to diagnose cardiac sarcoidosis?
Článek Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms
Článek Low-carbohydrate diet in diabetes mellitus treatment
Článek Endothelial function, its relation to arterial hypertension and the possibility of its modulation
Článek Myocardial injury after carbon monoxide intoxication in suicide attempt, with features of both toxic and tako-tsubo cardiomyopathy: case report
Článek Spironolactone in the treatment of hypertension: a neglected molecule
Článek Trimeresurus albolabris (white-lipped green pit viper) – bite report: case report
Článok vyšiel v časopise

Internal Medicine

Číslo 7-8
2018 Číslo 7-8
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#